Michael T. Constantino

CIK: 0001817285

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

HUMA

Humacyte, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

HUMA
Humacyte, Inc.
Jun 11, 2026
Award(A)
Stock Options (right to buy)
Direct
80K shares-
HUMA
Humacyte, Inc.
May 18, 2026
Purchase(P)
Direct
11K shares at avg. $0.89$10K
HUMA
Humacyte, Inc.
Jun 12, 2025
Award(A)
Stock Options (right to buy)
Direct
80K shares-
HUMA
Humacyte, Inc.
Apr 7, 2025
Purchase(P)
Direct
16K shares at avg. $1.26$20K
HUMA
Humacyte, Inc.
Dec 4, 2024
Purchase(P)
Direct
4.6K shares at avg. $4.39$20K

		Type	Shares	Price		Ownership
Jun 11, 2026	HUMA Humacyte, Inc.	Award(A) Stock Options (right to buy)	80,000	-	-	Direct
May 18, 2026	HUMA Humacyte, Inc.	Purchase(P)	11,000	$0.89	$9,840	Direct
Jun 12, 2025	HUMA Humacyte, Inc.	Award(A) Stock Options (right to buy)	80,000	-	-	Direct
Apr 7, 2025	HUMA Humacyte, Inc.	Purchase(P)	16,000	$1.26	$20,160	Direct
Dec 4, 2024	HUMA Humacyte, Inc.	Purchase(P)	4,600	$4.39	$20,181	Direct

1-5 of 5 transactions

About Constantino Michael T.

Constantino Michael T. (SEC CIK 0001817285) files insider reports with the SEC as Director of Humacyte, Inc. (HUMA).

Signal8 holds 5 ownership filings by Constantino Michael T., all Form 4s, filed between Dec 4, 2024 and Jun 12, 2026. Those filings report 5 transactions, from Dec 4, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Constantino Michael T.'s filings is in DURHAM, NC.

Recent filings by Constantino Michael T.

Jun 11, 2026: Grant or award of HUMA derivative securities (Form 4, code A).
May 18, 2026: Open-market purchase of HUMA shares (Form 4, code P).
Jun 12, 2025: Grant or award of HUMA derivative securities (Form 4, code A).
Apr 7, 2025: Open-market purchase of HUMA shares (Form 4, code P).
Dec 4, 2024: Open-market purchase of HUMA shares (Form 4, code P).

Other insiders filing for Humacyte, Inc. (HUMA)

COWARD D SCOTT, Director
Kuznik Paul Brian, Director
Jones Keith Anthony, Director
Windham-Bannister Susan Richards, Director
Wallace Max N., Director
Niklason Laura E, President, CEO and Director

How to read Form 4 transaction codes